CD22 Rabbit Monoclonal Antibody [Clone ID: hL22 (Epratuzumab)]

CAT#: TA386081

Recombinant Anti-CD22 (Clone hL22 (Epratuzumab))

Product Images

Flow-cytometry using anti-CD22 antibody Epratuzumab (TA386081) Human lymphocytes were stained with an isotype control (TA385644, panel A) or the rabbit-chimeric version of Eptratuzumab (TA386081, panel B) at a concentration of 1 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a AF488 conjugated donkey anti-rabbit antibody and cells analysed on a FACSCanto flow-cytometer.

• 

  Flow-cytometry using anti-CD22 antibody Epratuzumab (TA386081) Rhesus monkey lymphocytes were stained with an isotype control (TA385644, panel A) or the rabbit-chimeric version of Epratuzumab (TA386081, panel B) at a concentration of 1 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a AF488 conjugated donkey anti-rabbit antibody and cells analysed on a FACSCanto flow-cytometer.

• 

  Flow-cytometry using anti-CD22 antibody Epratuzumab (TA386081) Cynomolgus monkey lymphocytes were stained with an isotype control (TA385644, panel A) or the rabbit-chimeric version of Epratuzumab (TA386081, panel B) at a concentration of 1 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a AF488 conjugated donkey anti-rabbit antibody and cells analysed on a FACSCanto flow-cytometer.

Specifications

Product Data

• Clone Name: hL22 (Epratuzumab)
• Applications: Bl, FC, IP
• Reactivities: Human, Monkey
• Host: Rabbit
• Isotype: IgG, kappa
• Clonality: Monoclonal
• Immunogen: This antibody was prepared by the humanization of LL2 (EPB-2), a murine anti-CD22 IgG2a raised against Raji Burkitt lymphoma cells. Murine sequences comprise 5–10% of the molecule, with the remainder being human framework sequences, which greatly reduces the potential for immunogenicity (Traczewski, 2010).
• Specificity: This antibody is specific for the 3rd Ig-like domain of human CD22 (epitope B), a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells.
  
  Epratuzumab binds to the third extracellular domain of CD22, inducing CD22 phosphorylation, resulting in negative modulation of BCR activation, and rapid CD22 internalization, leading to modulation of B-cell homing (Traczewski, 2010). Initial phase II and two terminated early phase III studies suggest that the use of this antibody to treat systemic lupus erythematosus is effective and well tolerated, but both phase III trials failed to meet primary clinical efficacy endpoints. Additionally, in vitro studies and clinical trials indicate that this antibody can be used in combination therapy with another inhibitor of B-cell activity, rituximab (anti-CD20), in the treatment of non-Hodgkin lymphoma (Traczewski, 2010).
• Formulation: PBS with 0.02% Proclin 300.
• Concentration: lot specific
• Conjugation: Unconjugated
• Storage: Please store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C. Avoid freeze and thaw cycles.
• Stability: 3 years from dispatch.
• Gene Name: CD22 molecule
• Database Link:
  Entrez Gene 933 Human
  UniProt ID P20273
• Synonyms: BL-CAM; FLJ22814; Leu-14; MGC130020; Siglec-2; SIGLEC2
• Note: This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.